These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 23736031)

  • 1. p28, a first in class peptide inhibitor of cop1 binding to p53.
    Yamada T; Christov K; Shilkaitis A; Bratescu L; Green A; Santini S; Bizzarri AR; Cannistraro S; Gupta TK; Beattie CW
    Br J Cancer; 2013 Jun; 108(12):2495-504. PubMed ID: 23736031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nanotechnological, molecular-modeling, and immunological approach to study the interaction of the anti-tumorigenic peptide p28 with the p53 family of proteins.
    Coppari E; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
    Int J Nanomedicine; 2014; 9():1799-813. PubMed ID: 24748790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy.
    Bizzarri AR; Santini S; Coppari E; Bucciantini M; Di Agostino S; Yamada T; Beattie CW; Cannistraro S
    Int J Nanomedicine; 2011; 6():3011-9. PubMed ID: 22162658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the interaction between the p53 DNA-binding domain and the p28 peptide fragment of Azurin.
    Santini S; Bizzarri AR; Cannistraro S
    J Mol Recognit; 2011; 24(6):1043-55. PubMed ID: 22038811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination.
    Jia L; Gorman GS; Coward LU; Noker PE; McCormick D; Horn TL; Harder JB; Muzzio M; Prabhakar B; Ganesh B; Das Gupta TK; Beattie CW
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):513-24. PubMed ID: 21085965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p28, an anionic cell-penetrating peptide, increases the activity of wild type and mutated p53 without altering its conformation.
    Yamada T; Das Gupta TK; Beattie CW
    Mol Pharm; 2013 Sep; 10(9):3375-83. PubMed ID: 23952735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells.
    Yamada T; Mehta RR; Lekmine F; Christov K; King ML; Majumdar D; Shilkaitis A; Green A; Bratescu L; Beattie CW; Das Gupta TK
    Mol Cancer Ther; 2009 Oct; 8(10):2947-58. PubMed ID: 19808975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of the anticancer p28 peptide with p53-DBD as studied by fluorescence, FRET, docking and MD simulations.
    Bizzarri AR; Moscetti I; Cannistraro S
    Biochim Biophys Acta Gen Subj; 2019 Feb; 1863(2):342-350. PubMed ID: 30419285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of Amphipathic Cell Penetrating Peptide p28 to Wild Type and Mutated p53 as studied by Raman, Atomic Force and Surface Plasmon Resonance spectroscopies.
    Signorelli S; Santini S; Yamada T; Bizzarri AR; Beattie CW; Cannistraro S
    Biochim Biophys Acta Gen Subj; 2017 Apr; 1861(4):910-921. PubMed ID: 28126403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.
    Lulla RR; Goldman S; Yamada T; Beattie CW; Bressler L; Pacini M; Pollack IF; Fisher PG; Packer RJ; Dunkel IJ; Dhall G; Wu S; Onar A; Boyett JM; Fouladi M
    Neuro Oncol; 2016 Sep; 18(9):1319-25. PubMed ID: 27022131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt.
    Mehta RR; Yamada T; Taylor BN; Christov K; King ML; Majumdar D; Lekmine F; Tiruppathi C; Shilkaitis A; Bratescu L; Green A; Beattie CW; Das Gupta TK
    Angiogenesis; 2011 Sep; 14(3):355-69. PubMed ID: 21667138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ubiquitin ligase COP1 is a critical negative regulator of p53.
    Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
    Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
    Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
    Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raman Evidence of p53-DBD Disorder Decrease upon Interaction with the Anticancer Protein Azurin.
    Signorelli S; Cannistraro S; Bizzarri AR
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31238511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability.
    Su CH; Zhao R; Zhang F; Qu C; Chen B; Feng YH; Phan L; Chen J; Wang H; Wang H; Yeung SC; Lee MH
    Cancer Res; 2011 Feb; 71(3):884-94. PubMed ID: 21135113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular basis of Pirh2-mediated p53 ubiquitylation.
    Sheng Y; Laister RC; Lemak A; Wu B; Tai E; Duan S; Lukin J; Sunnerhagen M; Srisailam S; Karra M; Benchimol S; Arrowsmith CH
    Nat Struct Mol Biol; 2008 Dec; 15(12):1334-42. PubMed ID: 19043414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural basis of bacterial effector protein azurin targeting tumor suppressor p53 and inhibiting its ubiquitination.
    Hu J; Jiang W; Zuo J; Shi D; Chen X; Yang X; Zhang W; Ma L; Liu Z; Xing Q
    Commun Biol; 2023 Jan; 6(1):59. PubMed ID: 36650277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic p28 peptide targets essential H1N1 influenza virus proteins: insights from docking and molecular dynamics simulations.
    Sasidharan S; Gosu V; Shin D; Nath S; Tripathi T; Saudagar P
    Mol Divers; 2021 Aug; 25(3):1929-1943. PubMed ID: 33575983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours.
    Warso MA; Richards JM; Mehta D; Christov K; Schaeffer C; Rae Bressler L; Yamada T; Majumdar D; Kennedy SA; Beattie CW; Das Gupta TK
    Br J Cancer; 2013 Mar; 108(5):1061-70. PubMed ID: 23449360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 28-amino-acid peptide fragment of the cupredoxin azurin prevents carcinogen-induced mouse mammary lesions.
    Mehta RR; Hawthorne M; Peng X; Shilkaitis A; Mehta RG; Beattie CW; Das Gupta TK
    Cancer Prev Res (Phila); 2010 Oct; 3(10):1351-60. PubMed ID: 20841487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.